Market overview
The global pen injector market is worth USD 6.7 bn in 2026 and is forecast to reach USD 17.3 bn by 2036, growing at a 10.0% CAGR. United States is the largest country market and Disposable is the largest by type segment.
| Scope | Pen-type injectors for insulin, GLP-1, growth hormone, fertility and other drugs: disposable and reusable pens supplied to drug makers and patients. |
|---|---|
| Industry | Healthcare |
| Value 2025 | USD 6.0 bn |
| Value 2026 | USD 6.7 bn |
| Value 2036 | USD 17.3 bn |
| CAGR 2026-2036 | 10.0% |
| Volume 2026 | 2,900 million units |
| Volume 2036 | 7,910 million units |
| Average price 2026 | USD 2.30 per unit |
| Report price | Starts from USD 1,999 |
| Published | November 2026 |
Request a free sample of this report
Pen Injector market size and forecast, 2026-2036
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Year | Market value |
|---|---|
| 2026 | USD 6.7 bn |
| 2027 | USD 7.3 bn |
| 2028 | USD 8.1 bn |
| 2029 | USD 8.9 bn |
| 2030 | USD 9.8 bn |
| 2031 | USD 10.7 bn |
| 2032 | USD 11.8 bn |
| 2033 | USD 13.0 bn |
| 2034 | USD 14.3 bn |
| 2035 | USD 15.7 bn |
| 2036 | USD 17.3 bn |
Pen Injector market segmentation
By type
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Disposable | 58.0% | 62.5% | USD 3.9 bn | 10.8% |
| Reusable | 30.0% | 21.4% | USD 2.0 bn | 6.3% |
| Smart and connected | 12.0% | 16.1% | USD 799 mn | 13.3% |
By drug
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Insulin | 34.0% | 20.2% | USD 2.3 bn | 4.4% |
| GLP-1 and obesity | 42.0% | 62.0% | USD 2.8 bn | 14.4% |
| Growth hormone | 7.0% | 5.0% | USD 466 mn | 6.4% |
| Fertility | 5.0% | 3.3% | USD 333 mn | 5.4% |
| Osteoporosis and other | 12.0% | 9.5% | USD 799 mn | 7.4% |
By end user
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Home care | 70.0% | 73.9% | USD 4.7 bn | 10.6% |
| Hospitals | 18.0% | 15.1% | USD 1.2 bn | 8.1% |
| Clinics and long-term care | 12.0% | 11.0% | USD 799 mn | 9.1% |
By drug category
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Insulin and diabetes drugs | 48.0% | 42.0% | USD 3.2 bn | 8.5% |
| Growth hormone | 14.0% | 13.0% | USD 932 mn | 9.2% |
| Fertility and osteoporosis drugs | 14.0% | 14.0% | USD 932 mn | 10.0% |
| GLP-1 and weight management | 24.0% | 31.0% | USD 1.6 bn | 12.8% |
By channel
| Segment | Share 2026 | Share 2036 | Value 2026 | CAGR 2026-36 |
|---|---|---|---|---|
| Retail pharmacy | 48.0% | 44.0% | USD 3.2 bn | 9.1% |
| Hospital pharmacy | 22.0% | 20.0% | USD 1.5 bn | 9.0% |
| Online pharmacy | 30.0% | 36.0% | USD 2.0 bn | 12.0% |
Top 25 countries for pen injector by revenue
Countries are ranked by revenue earned from sales in the country, not by where the product is made. The ten largest hold 79.5% of 2026 revenue and the 25 countries below together hold 94.7%.
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
| # | Country | Value 2026 | Share 2026 | Value 2036 | CAGR 2026-36 |
|---|---|---|---|---|---|
| 1 | United States | USD 2.4 bn | 36.0% | USD 6.4 bn | 10.3% |
| 2 | China | USD 799 mn | 12.0% | USD 2.8 bn | 13.3% |
| 3 | Germany | USD 333 mn | 5.0% | USD 674 mn | 7.3% |
| 4 | Japan | USD 333 mn | 5.0% | USD 674 mn | 7.3% |
| 5 | United Kingdom | USD 266 mn | 4.0% | USD 587 mn | 8.2% |
| 6 | France | USD 266 mn | 4.0% | USD 536 mn | 7.2% |
| 7 | India | USD 266 mn | 4.0% | USD 846 mn | 12.3% |
| 8 | Brazil | USD 233 mn | 3.5% | USD 570 mn | 9.3% |
| 9 | Italy | USD 200 mn | 3.0% | USD 397 mn | 7.1% |
| 10 | Canada | USD 200 mn | 3.0% | USD 484 mn | 9.2% |
| 11 | Spain | USD 136 mn | 2.0% | USD 330 mn | 9.3% |
| 12 | Netherlands | USD 119 mn | 1.8% | USD 290 mn | 9.3% |
| 13 | Mexico | USD 105 mn | 1.6% | USD 256 mn | 9.3% |
| 14 | Australia | USD 100 mn | 1.5% | USD 244 mn | 9.3% |
| 15 | Turkey | USD 91 mn | 1.4% | USD 221 mn | 9.3% |
| 16 | Russia | USD 81 mn | 1.2% | USD 195 mn | 9.2% |
| 17 | Poland | USD 71 mn | 1.1% | USD 171 mn | 9.2% |
| 18 | South Korea | USD 62 mn | 0.9% | USD 150 mn | 9.3% |
| 19 | Sweden | USD 51 mn | 0.8% | USD 123 mn | 9.2% |
| 20 | Switzerland | USD 43 mn | 0.7% | USD 104 mn | 9.1% |
| 21 | Belgium | USD 38 mn | 0.6% | USD 92 mn | 9.2% |
| 22 | Argentina | USD 36 mn | 0.5% | USD 88 mn | 9.4% |
| 23 | Saudi Arabia | USD 29 mn | 0.4% | USD 71 mn | 9.2% |
| 24 | Denmark | USD 26 mn | 0.4% | USD 62 mn | 9.1% |
| 25 | Austria | USD 23 mn | 0.3% | USD 55 mn | 9.3% |
| Rest of world | USD 355 mn | 5.3% | USD 883 mn | 9.5% |
Source: Compare Market Research analysis.
© 2026 Compare Market Research. All rights reserved.
Competitive landscape
Group 1: Global leaders
- Novo Nordisk
- Eli Lilly
- Ypsomed
- SHL Medical
- Phillips-Medisize
Group 2: Regional and specialist players
- Becton Dickinson
- Owen Mumford
- Haselmeier
- Sanofi
- Nemera
- West Pharmaceutical Services
- Terumo
- Halozyme
Group 3: Emerging and niche players
- Gan & Lee
- Biocon
- Biocorp
- Subcuject
- Julphar
- Tonghua Dongbao
Research methodology
Every figure on this page comes from the research framework that we apply to all of the markets we cover. The 2025 base for the pen injector market is built from the volume sold and the price that buyers pay, and is cross-checked against the size of the wider industry the market belongs to. Where a market can be sized in more than one way, the routes are compared before a figure is set.
The forecast runs year by year from the 2025 base to 2036. Growth in each year reflects demand from the industries that buy the product, adoption of new technology, pricing, regulation and replacement cycles. Volume and price are modelled together, so revenue in each year equals volume multiplied by average price. The 2026 to 2036 compound annual growth rate of 10.0% is calculated from the resulting values.
The market is divided by type, by drug, by end user, by drug category, by channel. The 25 largest countries are ranked by revenue earned from sales to buyers in each country, not by where the product is made. Segment values and country values add up to the market total in every year, and every report is checked for consistency before it is published.
Companies are placed in three groups: global leaders, regional and specialist players, and emerging and niche players. The groups describe how companies compete in the market. They are not a ranking and they are not market shares.
Our analysts also carry out primary research. Customized reports add interviews with key opinion leaders, such as senior executives, technical specialists and buyers, to test the assumptions behind the numbers for the question being asked.
Frequently asked questions
How big is the pen injector market?
The global pen injector market is estimated at USD 6.0 bn in 2025 and USD 6.7 bn in 2026.
How fast will the pen injector market grow?
It is forecast to reach USD 17.3 bn by 2036, a compound annual growth rate of 10.0% from 2026, an increase of USD 10.6 bn.
Which country is the largest market for pen injector?
United States is the largest market by revenue at USD 2.4 bn in 2026, 36.0% of the global total. The three largest countries together hold 53.0%.
Which country is growing fastest?
Among the ten largest markets, China is growing fastest at 13.3% a year from 2026 to 2036.
Which pen injector segment is largest?
In the by type split, Disposable is the largest segment with 58.0% of 2026 revenue.
Who are the leading pen injector companies?
Global leaders include Novo Nordisk, Eli Lilly, Ypsomed, SHL Medical.
Need the full report?
Request a sample to see the structure, tables and country detail.
Request a free sampleRelated markets in Healthcare
- Mass SpectrometryUSD 6.6 bn · 7.0% CAGR
- Cleanroom ConsumableUSD 6.7 bn · 7.5% CAGR
- Fiber SupplementsUSD 6.4 bn · 6.5% CAGR
- Infusion PumpUSD 6.9 bn · 5.2% CAGR
- UltrafiltrationUSD 6.4 bn · 9.5% CAGR
- Laboratory AutomationUSD 7.0 bn · 8.0% CAGR
- Retail ClinicUSD 6.3 bn · 5.3% CAGR
- Good Manufacturing Practice ComplianceUSD 6.3 bn · 8.5% CAGR
← Patient-Specific Surgical Implant Design Peptide Receptor Radionuclide Therapy (PRRT) →